title: [Molecular targeting therapy for multiple myeloma].
abstract: Molecular target therapy is the most progressive and promising anticancer therapy in last decade. Multiple myeloma is also one of the major therapeutic targets for using molecular based technology. The recent availability of clinical data regarding thalidomide-, lenalidomide-, and bortezomib-based regimens has provided new, effective treatment options for patients with both newly diagnosed and relapsed/refractory multiple myeloma. We are expecting that future clinical trials can be designed to achieve a high likelihood of success based on molecular studies, cell-signaling, and correlative science studies. Studies with these agents also provide new insight into the cancer biology underlying multiple myeloma in humans.
authors: Clinical Development, Celgene KK.
authors: Masaaki
authors: M
authors: Takatoku
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use; D000068258:Bevacizumab; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000209:etiology; D010087:Oxides / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001152:Arsenicals; D001897:Boronic Acids; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D007166:Immunosuppressive Agents; D010087:Oxides; D011480:Protease Inhibitors; D011719:Pyrazines; D053221:TNF-Related Apoptosis-Inducing Ligand; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D013792:Thalidomide; D000069286:Bortezomib; D051231:Farnesyltranstransferase; D000077269:Lenalidomide; D000077237:Arsenic Trioxide